Lv31
206 积分 2025-03-10 加入
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
1年前
已完结
Innovative Applications of Bacteria and Their Derivatives in Targeted Tumor Therapy
1年前
已完结
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
1年前
已完结
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
1年前
已完结
皖公网安备34019202002308
